Syros to present new clinical data at ASCO 2023
Biopharmaceutical company Syros Pharmaceuticals has announced new clinical data from the Phase I/Ib clinical trial evaluating SY-5609 in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumours. The data will be presented in two posters at the 2023 American Society for… Read More